Endocrine
circa 1815, France — Michel Eugène Chevreul, isolation of cholesterine from gallstones
The history of hypercholesterolemia as a medical concept unfolded over more than a century, tracing a path from early biochemical curiosity to one of the most intensely studied risk factors in cardiovascular medicine. Physicians and researchers across Europe and North America gradually assembled the evidence linking elevated blood cholesterol to arterial disease, transforming a laboratory finding into a cornerstone of preventive cardiology. The condition's history illuminated the slow, contested nature of medical consensus-building.
Historical Narrative
Cholesterol itself was first isolated by the French chemist Michel Eugène Chevreul in the early nineteenth century, who extracted a waxy substance from gallstones and named it cholesterine, from the Greek words for bile and solid. For decades, cholesterol remained primarily a subject of biochemical interest rather than clinical concern, studied for its structural properties and its presence in various bodily tissues without any clear understanding of its role in disease.
The critical observational link between cholesterol and arterial disease began to emerge in the early twentieth century through the work of the Russian pathologist Nikolai Anichkov. Beginning around 1913, Anichkov and his colleague Semen Chalatov conducted experiments in which they fed rabbits diets rich in cholesterol and observed the subsequent development of fatty deposits in the animals' arterial walls — lesions strikingly similar to the atherosclerotic plaques found in human arteries. Anichkov proposed that dietary cholesterol was the primary driver of atherosclerosis, a hypothesis that was initially met with skepticism, partly because rabbits were herbivores and critics questioned whether findings in such animals were applicable to humans.
In the 1930s and 1940s, clinicians began documenting familial patterns of very high blood cholesterol levels associated with premature and severe cardiovascular disease. The Norwegian physician Carl Müller described what he termed xanthomatosis in 1938, identifying families in which elevated blood cholesterol, characteristic fatty skin deposits called xanthomas, and early heart disease clustered together across generations. Müller recognized the hereditary nature of the condition, laying the groundwork for later understanding of what would be called familial hypercholesterolemia.
The postwar period produced the most influential epidemiological investigation in the history of hypercholesterolemia. The American physiologist Ancel Keys conducted the Seven Countries Study beginning in the late 1950s, examining the relationships among diet, blood cholesterol levels, and cardiovascular mortality across cohorts in the United States, Finland, the Netherlands, Italy, Yugoslavia, Greece, and Japan. Keys reported strong associations between saturated fat intake, serum cholesterol, and coronary heart disease rates, conclusions that reoriented public health thinking about diet and heart disease for decades, though his methodology and conclusions later attracted sustained criticism from other researchers.
John Gofman at the University of California used ultracentrifuge technology in the late 1940s and 1950s to separate cholesterol-carrying proteins in blood by density, distinguishing what he described as different lipoprotein fractions with varying associations with cardiovascular risk. His work introduced the conceptual framework that would eventually yield the clinical distinction between low-density and high-density lipoproteins.
The most transformative biochemical discoveries came in the 1970s, when Michael Brown and Joseph Goldstein at the University of Texas Southwestern Medical Center elucidated the cellular receptor mechanism governing cholesterol uptake. Their work, for which they received the Nobel Prize in Physiology or Medicine in 1985, explained at a molecular level why individuals with familial hypercholesterolemia accumulated dangerously elevated cholesterol levels in their blood, cementing the condition's place as a central subject in both biochemistry and clinical medicine.
Key Historical Figures
Historical narrative only — this page describes how Hypercholesterolemia was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.